Page 10 - Orvosoktatás - Gyakorlati útmutatás

Referenciák: ease). J Am Coll Cardiol. 2010 Dec
14;56(25):2147-81.
1. Criqui MH, Fronek A, Klauber MR, 7. Dawson DL, Cutler BS, Meissner MH,
et al. The sensitivity, specificity, and et al. Cilostazol has beneficial effects
predictive value of traditional clinical in treatment of intermittent claudica-
evaluation of peripheral arterial dis- tion. Results from a multicenter, ran-
ease: results from noninvasive testing domized, prospective, doubleblind
in a defined population. Circulation. trial. Circulation 1998; 98: 678-86.
1985;71:516–522. 8. Beebe HG, Dawson DL, Cutler BS, et
2. Bhatt, D.L. és mtsai. REACH Investi- al. Cilostazol, a new treatment for inter-
gation: Presented at: American Col- mittent claudication: results of a ran-
lege of Cardiology Annual Scientific domized, multicenter trial [abstract].
Session; March 8, 2005, Orlando, FL. Circulation 1997; 96 Suppl.: I-12.
Abstract 1127-1196. 9. Money SR, Herd JA, Isaacsohn JL,
3. Kornitzer, M., Dramaix, M., Sobolski, et al. Effect of cilostazol on walking
J. és mtsai: Ankle-arm pressure index distances in patients with intermittent
in asymptomatic middle aged males: claudication caused by peripheral
an independent predictor of ten year vascular disease. J Vasc Surg 1998;
coronary heart disease mortality. An- 27:267-75.
giology, 1995, 46, 211-219. 10. Dawson DL, Beebe HG, Davidson
4. ESC Guidelines on the diagnosis MH, et al. Cilostazol or pentoxifylline
and treatment of peripheral artery for claudication? [abstract no. 58].
dieseases European Heart Journal Circulation 1998; 98 (17) Suppl. 1: I-1
(2011) 32, 2851–2906 11. William R. Hiatt, MD,a Samuel R.
5. Gardner AW1, Poehlman ET. Exer- Money, MD,b and Eric P. Brass, MD,
cise rehabilitation programs for the Long-term safety of cilosztazol in
treatment of claudication pain. patients with peripheral artery dis-
A meta-analysis. JAMA. 1995 Sep ease: The CASTLE study (Cilostazol:
27;274(12):975-80. A Study in Long-term Effects) J Vasc
6. Olin JW, Allie DE, Belkin M, Bonow Surg 2008;47:330-6.
RO, Casey DE Jr, Creager MA, et al. 12. Reena L Pande1, William R Hiatt2,
ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/ Peter Zhang et al. A pooled analysis
SVS 2010 performance measures for of the durability and predictors of
adults with peripheral artery disease: treatment response of cilostazol in
a report of the American College of patients with intermittent claudica-
Cardiology Foundation/American tion Vasc Med 2010 15: 181.
Heart Association Task Force on 13. L. Norgren, W.R. Hiatt, J.A. Dorman-
Performance Measures, the Amer- dy, M.R. Nehler, K.A. Harris, and F.G.R.
ican College of Radiology, the So- Fowkes Inter-Society Consensus for
ciety for Cardiac Angiography and the Management of Peripheral Arte-
Interventions, the Society for Inter- rial Disease (TASC II) JOURNAL OF
ventional Radiology, the Society for VASCULAR SURGERY
Vascular Medicine, the Society for 14. Volume 45, Number 1, Supplement
Vascular Nursing, and the Society for S 2007
Vascular Surgery (Writing Commit- 15. Angiolillo DJ et al.OPTIMUS-2 study.
tee to Develop Clinical Performance European Heart Journal (2008) 29,
Measures for Peripheral Artery Dis- 2202–2211.)

10